|Dr. Robert Erik Holmlin M.B.A., Ph.D.||Pres, CEO, Sec. & Director||660.84k||N/A||1968|
|Mr. Mark Oldakowski||Chief Operating Officer||487.73k||N/A||1974|
|Mr. Richard Shippy||Chief Bus. Officer & Head of Global Sales||321.72k||N/A||1971|
|Mr. Christopher P. Stewart||Chief Financial Officer||N/A||N/A||1970|
|Ms. Helene Klein||Chief People Officer||N/A||N/A||N/A|
|Dr. Alka Chaubey FACMG, Ph.D.||Chief Medical Officer||N/A||N/A||1973|
|Dr. Soheil Shams Ph.D.||Chief Informatics Officer||N/A||N/A||1965|
|Dr. Paul R. Selvin Ph.D.||Scientific Advisor||N/A||N/A||N/A|
|Prof. Pui-Yan Kwok M.D., Ph.D.||Scientific Advisor||N/A||N/A||N/A|
Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.
Bionano Genomics, Inc.’s ISS governance QualityScore as of 1 July 2022 is 10. The pillar scores are Audit: 9; Board: 8; Shareholder rights: 8; Compensation: 10.